Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 8Completed 6Recruiting 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Lymphatic Metastasis 1

Interventions

Specimen Handling 480pembrolizumab 455Magnetic Resonance Spectroscopy 420Carboplatin 327Cyclophosphamide 314Cisplatin 271Biopsy 271Radiotherapy 244Paclitaxel 229Gemcitabine 227Bevacizumab 213Nivolumab 188fludarabine 185venetoclax 174Drug Therapy 170Blood Specimen Collection 158Dexamethasone 157Oxaliplatin 154Injections 152Capecitabine 151Fluorouracil 144Docetaxel 144Radiosurgery 137Standard of Care 135Rituximab 125Pemetrexed 117durvalumab 115Leucovorin 109atezolizumab 107Radiation 106

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × radium Ra 223 dichloride × 1 year × Clear all
NCT07611110 2026-05-28

VECTRA-01

AstraZeneca

Phase 3 Recruiting
670 enrolled
Genitourinary

Prostatic Neoplasms

NCT04071236 2026-05-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

National Cancer Institute (NCI)

Phase 1/2 Recruiting
90 enrolled
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT04489719 2026-02-17

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

University of Washington

Recruiting
48 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡